Immunology | New Developments | UNITED STATES

Atomwise

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Atomwise, Bridge Biotherapeutics pen $1B deal for AI-devised molecules

Lead Product(s): Undisclosed

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Bridge Biotherapeutics

Deal Size: $1,080.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration March 09, 2020

Details:

Under the agreement, Atomwise will evaluate and initiate programs for Pellino E3 ubiquitin ligases and other targets nominated by Bridge.

Alladapt Immunotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing

Lead Product(s): ADP101

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Gurnet Point Capital

Deal Size: $60.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing February 20, 2020

Details:

Proceeds to support clinical advancement of ADP101, a broad-spectrum oral biopharmaceutical candidate targeting food allergy.

Sonoma Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Sonoma bags $40M to push Tregs for autoimmune, neuro diseases

Lead Product(s): Treg therapy

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Lyell Immunopharma

Deal Size: $40.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing February 06, 2020

Details:

The series A funding is to advance regulatory T cell therapy in autoimmune and degenerative diseases.

AgeX Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells

Lead Product(s): Hypoimmunogenic cells

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 29, 2020

Details:

First research collaboration for immunotolerance UniverCyteTM technology platform, marking launch of new business development and collaboration strategy.

Quench Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases

Lead Product(s): Undisclosed

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: RA Capital Management

Deal Size: $50.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 27, 2020

Details:

The funding will support company's lead therapeutic approach that inhibits Gasdermin D, which has been recently discovered as a key target at the core of multiple inflammatory cell death pathways.

Kyverna Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Kyverna Therapeutics Secures $25 Million Series A Funding

Lead Product(s): T cells therapy

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Vida Ventures

Deal Size: $25.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 13, 2020

Details:

Proceeds from the financing will be used to advance Kyverna's therapeutic strategy which combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate autoreactive immune cells at the root cause of inflammatory disease.

Kyverna Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Kyverna Therapeutics Enters into Strategic Collaboration with Gilead Sciences

Lead Product(s): T cells therapy

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Gilead Sciences

Deal Size: $587.5 million Upfront Cash: $17.5 million

Deal Type: Collaboration January 13, 2020

Details:

Kyverna will be conducting research activities and initial clinical studies through proof-of-concept and Gilead will be granted an option for further development and commercialization of these programs.

Ligand Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics

Lead Product(s): Antibodies

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Pandion Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 13, 2020

Details:

Under the agreement, Pandion will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™.

CSL Behring

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

SAB Biotherapeutics Announces Research Collaboration With CSL Behring

Lead Product(s): Undisclosed

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: SAb Biotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 07, 2020

Details:

The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb™ platform.

Find

Find Novel Immunology Drugs in Clinical Development in UNITED STATES

United States

A collaboration with SCORR Marketing

Product Type

Companies

Atomwise

Atomwise, Bridge Biotherapeutics pen $1B deal for AI-devised molecules

Alladapt Immunotherapeutics

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing

Sonoma Biotherapeutics

Sonoma bags $40M to push Tregs for autoimmune, neuro diseases

AgeX Therapeutics

AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells

Quench Bio

Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases

Kyverna Therapeutics

Kyverna Therapeutics Secures $25 Million Series A Funding

Kyverna Therapeutics

Kyverna Therapeutics Enters into Strategic Collaboration with Gilead Sciences

Ligand Pharmaceuticals

Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics

CSL Behring

SAB Biotherapeutics Announces Research Collaboration With CSL Behring